1. Home
  2. PJT vs CRSP Comparison

PJT vs CRSP Comparison

Compare PJT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PJT
  • CRSP
  • Stock Information
  • Founded
  • PJT 2014
  • CRSP 2013
  • Country
  • PJT United States
  • CRSP Switzerland
  • Employees
  • PJT N/A
  • CRSP N/A
  • Industry
  • PJT Investment Managers
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PJT Finance
  • CRSP Health Care
  • Exchange
  • PJT Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • PJT 3.8B
  • CRSP 3.4B
  • IPO Year
  • PJT N/A
  • CRSP 2016
  • Fundamental
  • Price
  • PJT $148.26
  • CRSP $41.59
  • Analyst Decision
  • PJT Hold
  • CRSP Buy
  • Analyst Count
  • PJT 5
  • CRSP 19
  • Target Price
  • PJT $148.00
  • CRSP $74.35
  • AVG Volume (30 Days)
  • PJT 339.6K
  • CRSP 1.5M
  • Earning Date
  • PJT 05-01-2025
  • CRSP 05-07-2025
  • Dividend Yield
  • PJT 0.68%
  • CRSP N/A
  • EPS Growth
  • PJT 57.58
  • CRSP N/A
  • EPS
  • PJT 4.92
  • CRSP N/A
  • Revenue
  • PJT $1,495,177,000.00
  • CRSP $37,314,000.00
  • Revenue This Year
  • PJT $10.02
  • CRSP $49.76
  • Revenue Next Year
  • PJT $11.25
  • CRSP $257.28
  • P/E Ratio
  • PJT $29.92
  • CRSP N/A
  • Revenue Growth
  • PJT 29.26
  • CRSP N/A
  • 52 Week Low
  • PJT $88.51
  • CRSP $36.52
  • 52 Week High
  • PJT $190.27
  • CRSP $73.09
  • Technical
  • Relative Strength Index (RSI)
  • PJT 45.40
  • CRSP 45.94
  • Support Level
  • PJT $140.92
  • CRSP $40.41
  • Resistance Level
  • PJT $144.53
  • CRSP $42.72
  • Average True Range (ATR)
  • PJT 4.30
  • CRSP 1.98
  • MACD
  • PJT 0.97
  • CRSP -0.17
  • Stochastic Oscillator
  • PJT 84.29
  • CRSP 23.99

About PJT PJT Partners Inc.

PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement fees, and others. Geographically, It generates a majority of its revenue from the United States.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: